Admescope

What Admescope does

Admescope (legally Symeres Finland Oy) is a Finnish contract research organization (CRO) founded in 2011 and headquartered in Oulu, Finland, that provides preclinical ADME-Tox (Absorption, Distribution, Metabolism, Excretion, and Toxicity) and DMPK services to the pharmaceutical, biotechnology, and veterinary industries. The company operates a comprehensive service platform spanning in vitro metabolism, drug-drug interactions (including CYP/UGT inhibition/induction and transporter interaction studies across 9 transporter systems), in vivo DMPK, quantitative bioanalysis (LC-MS/MS and LC-HR/MS), permeability and transporter assays, physicochemistry and binding, in vitro toxicology (including the proprietary DILIscope hepatotoxicity screening package), biologics characterization (ADCs, oligonucleotides, antibodies), safety metabolism, and rapid-turnaround early ADME screening. Its technology stack rests on advanced analytical instrumentation (UPLC-HR/MS, LC-MS/MS, radiodetection, SPR, BLI, qPCR, automated fluorescence microscopy, high-content imaging) rather than AI/ML systems.

Since 2020, Admescope has operated as part of Symeres, an integrated CRDMO with over 600 scientists across the Netherlands, Czech Republic, USA, and Finland, enabling cross-sell of medicinal chemistry and integrated drug discovery services. The company generates revenue through fee-for-service, quote-based project contracts (often multi-year), complemented by an e-commerce portal (Admeshop) for self-serve quote requests, and serves customers across more than 30 countries and five continents via a direct business development team with regional coverage (Boston for North America; Dr. Laszlo Szilagyi for Europe and APAC). Operations run under a non-GLP quality management system, with services explicitly designed to support FDA and EMA regulatory submissions.

Name

Admescope

Legal name

Symeres Finland Oy

Website

https://admescope.com

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

11–50 employees

Short description

Admescope (Symeres Finland Oy) is a Finnish preclinical CRO providing ADME-Tox, DMPK, and drug-drug interaction services to pharmaceutical, biotechnology, and veterinary companies across more than 30 countries. Since 2020 it has operated within the Symeres CRDMO group.

Ownership category

akta.pro rank

Product category

Preclinical ADME-Tox Contract Research

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

DMPK / ADME & Bioanalysis (HLAGAFAC)

akta.pro secondary industries

Preclinical CROs (Discovery/Pharmacology/DMPK) (HLAGAAAB), Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity) (HLAGAAAD)

Keywords

• Preclinical ADME services
• Drug-drug interaction studies
• In vitro metabolism
• DMPK contract research
• Pharmacokinetic analysis

Headquarters

HQ city

Oulu

HQ country

Finland

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Contract Research Services (ADME-Tox): Admescope generates revenue through fee-for-service contract research agreements for preclinical ADME-Tox and DMPK studies. Services are quoted and delivered on a project-by-project basis, with pricing based on study type, complexity, compound requirements, and turnaround time. The company operates an e-commerce portal (Admeshop) where customers can request quotes and access selected service packages.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

Admescope is a Finnish contract research organization (CRO) providing premium, tailor-made ADME-Tox (Absorption, Distribution, Metabolism, Excretion, and Toxicity) and DMPK services to the pharmaceutical, biotechnology, and veterinary industries. Its offering covers the full preclinical ADME workflow including in vitro metabolism, drug-drug interaction studies, in vivo pharmacokinetics, quantitative bioanalysis, permeability and transporter assays, physicochemistry, in vitro toxicology (including the DILIscope hepatotoxicity platform), biologics characterization (including ADCs and oligonucleotides), safety metabolism, and early ADME screening. Services are sold as project-based contracts, delivered via a global direct sales team and the Admeshop self-service portal.

Product overview

Admescope is a preclinical contract research organization (CRO) providing a comprehensive portfolio of ADME-Tox (Absorption, Distribution, Metabolism, Excretion, and Toxicity) services for drug discovery and development. The company operates as a unified service platform rather than a single product, offering interconnected testing services including in vitro metabolism, drug interactions, in vivo DMPK, quantitative bioanalysis, permeability and transporter studies, physicochemistry and binding, in vitro toxicology (including the DILIscope hepatotoxicity package), biologics characterization, safety metabolism, early ADME screening, and custom research services. Services are available for all drug modalities including small molecules, peptides, oligonucleotides, antibodies, and ADCs. Since 2020, Admescope has been part of Symeres, enabling access to integrated drug discovery capabilities.

Differentiator

Problem solved

Functional benefit

Products and services

• In Vitro Metabolism Drug metabolism studies evaluating metabolic fate in liver and extrahepatic tissues using various enzyme sources, supporting metabolite identification, phenotyping, and clearance predictions for drug discovery and development programs.
• Drug Interactions Comprehensive drug-drug interaction assessment including CYP/UGT inhibition and induction studies, transporter interaction studies, and enzyme phenotyping to support FDA and EMA regulatory compliance.
• In Vivo DMPK In vivo pharmacokinetic studies in multiple species including rodent studies with AAALAC-accredited facilities, supporting exposure, clearance, and metabolism characterization for preclinical drug development.
• Quantitative Bioanalysis Comprehensive bioanalytical services using LC-MS/MS and LC-HR/MS for quantification of small molecules, peptides, oligonucleotides, antibodies, and ADCs across biological matrices.
• Permeability and Transporters Permeability assays including PAMPA, Caco-2, and MDCK studies, plus efflux and uptake transporter interaction assessments for substrate and inhibition evaluation. Includes BCS classification Caco-2 permeability assessment aligned with ICH M9 guidance.
• Physicochemistry and Binding Evaluation of solubility, lipophilicity (logP/D), plasma protein binding, blood-to-plasma ratio, tissue binding, and stability in biological and biorelevant media.
• In Vitro Toxicology Early-stage safety assessment including DILIscope hepatotoxicity screening, genotoxicity (AMES, MNT), cytotoxicity, cardiotoxicity (hERG), and mechanistic toxicity assays.
• Biologics ADME-Tox and DMPK services for biologics including ADC characterization, oligonucleotide studies, protein quantification (LC-MS/ELISA), and structural characterization.
• Safety Metabolism Metabolite profiling and MIST (Metabolites in Safety Testing) analysis to identify disproportionate or unique human metabolites and support preclinical safety qualification.
• Early ADME Automated high-throughput early ADME screening with rapid turnaround (within one week) for solubility, logD, metabolic stability, plasma protein binding, and CYP inhibition.
• Custom Services Tailored custom research and ad hoc experiments designed to address specific research questions not covered by standard assay portfolios.
• DILIscope Hepatotoxicity Screening Comprehensive hepatotoxicity and drug-induced liver injury (DILI) screening service package using primary human hepatocytes and high-content imaging, covering steatosis, phospholipidosis, lysosomal trapping, and cell stress endpoints.

Quantifiable outcome

• Early ADME screening data available within one week for frequently requested assays
• +1 more outcomes

Named customers2 records

Segments2 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Four partnerships are on record, tiered core and minor.

• SymerescoreStrategic or Co-development PartnerSince 2020, Admescope has been part of Symeres, an integrated CRDMO (Contract Research, Development and Manufacturing Organization). This parent company relationship enables Admescope to provide medicinal chemistry and integrated drug discovery & development services through the Symeres organization. Symeres operates multiple locations across the Netherlands, Czech Republic, USA, and Finland with over 600 scientists.
• European In-life PartnersminorChannel Partner/ Reseller/ DistributorAdmescope partners with AAALAC-accredited and GLP-compliant European in-life partners for studies requiring species beyond their in-house rodent facilities (mice and rats). Each partnership is chosen based on study requirements including animal species, sample type, and radiolabeled vs non-labeled compound needs.
• External Cardiac Safety PartnersminorStrategic or Co-development PartnerFor comprehensive electrophysiological cardiac safety panels beyond the hERG screening assay, Admescope refers customers to partner organizations offering full cardiac safety testing services.
• Custom Synthesis and Metabolite Production PartnersminorStrategic or Co-development PartnerFor metabolites where chemical synthesis is not feasible through Symeres' custom synthesis services, Admescope partners with microbial biotransformation companies to produce metabolites for客户 projects.

Scale indicators3 records

Recent moves1 record

Expansion highlights5 records

Direct peers

• Sai Life Sciences: Mid-tier CRO with ADME, DMPK, in vitro toxicology and bioanalysis capabilities. Comparable positioning as a scientifically focused, mid-sized preclinical CRO serving global pharma/biotech.
• Pharmaron: Integrated CRO/CDMO with strong DMPK, in vitro/in vivo ADME and biologics capabilities. Competes with Admescope especially on integrated discovery/preclinical packages and biologics ADME.
• BioIVT: Provides in vitro ADME services plus biospecimens and primary hepatocytes. Direct competitor on hepatocyte-based assays, DDI screening and early ADME packages.
• Cyprotex (Evotec): Specialist preclinical ADME-Tox and DMPK CRO within Evotec, offering in vitro ADME, DDI, permeability and in vivo PK. Most direct competitor to Admescope on the ADME/DMPK service menu for small molecules and increasingly biologics.
• Eurofins Discovery: Eurofins' drug discovery services arm offers in vitro ADME, DMPK, pharmacology and toxicology panels similar to Admescope. Comparable in scientific breadth and global reach, with larger parent scale.
• Sekisui Xenotech: Specialist in drug metabolism, transporter-mediated DDI and bioanalysis with deep CYP and transporter assay portfolios. Closely matches Admescope's DDI, CYP inhibition/induction and transporter offerings.

Broad incumbents

• Charles River Laboratories: Largest preclinical CRO with extensive ADME, DMPK, safety assessment and biologics capabilities. Competes on enterprise pharma accounts; Admescope's CEO previously held roles there.
• Labcorp Drug Development (Fortrea): Large CRO with broad preclinical ADME-Tox, bioanalytical and clinical CRO capabilities. Overlaps with Admescope on DMPK, DDI and bioanalysis but at materially larger scale and GLP reach.
• WuXi AppTec (STA Pharmaceutical): Global CRDMO with integrated discovery, DMPK and bioanalytical services. Competes for integrated preclinical packages; significantly larger and broader than Admescope.

Emerging players

• Bioneer (in vivo DMPK partner): Specialized in vivo DMPK and ADME CRO with rodent PK and bioanalytical capabilities. Comparable niche focus on in vivo pharmacokinetics for small molecules and biologics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@Admescope
• LinkedInlinkedin.com/company/admescope
• Xx.com/admescope
• Facebookfacebook.com/admescope

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Admescope